leisure time -WSS

leisure time

author：leisure time 2025-09-30 17:27:59 - browse：794

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Healthy food access boosts outcomes in two studies

focus

WSS

Healthy food access boosts outcomes in two studies

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

STAT's guide to the next generation of CAR

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Healthy food access boosts outcomes in two studies

Donald Trump's relentless attacks on special counsel Jack Smith

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Jerome Adams on the need for new antivirals for Covid

What is STAT's opinion section for?

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

In Memoriam: Notable people who died in 2023

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Medical leaders decry Supreme Court decision on affirmative action

3 hurdles to bringing medical devices to the U.S. market

United colonoscopy coverage change 'may cost lives,' doctors say

STAT's guide to the next generation of CAR

entertainment

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Weight bias in eating disorder treatment complicated by new weight loss drugs

The science behind Janet Jackson's pregnancy at 49

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Today's health inequities arise from racist U.S. history, say experts

Ohio still needs to do more to protect the right to abortion

focus

entertainment

focus

knowledge